{"id":240822,"date":"2026-09-10T12:40:23","date_gmt":"2026-09-10T07:10:23","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=240822"},"modified":"2026-09-10T12:40:23","modified_gmt":"2026-09-10T07:10:23","slug":"multibagger-pharma-stock-rises-129-percent-in-1-year","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/multibagger-pharma-stock-rises-129-percent-in-1-year\/","title":{"rendered":"This Multibagger Pharma Stock Rises 129% in 1 Year: What Is Powering the CDMO Rally?"},"content":{"rendered":"

CMP around Rs 1,940 (10 Sep 2026). 1-year return 129.01%. 52W range Rs 823.10 to Rs 1,955. Market cap Rs 1,04,456 Cr. Q1 FY27 PAT approx Rs 362 Cr vs Rs 161 Cr.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Laurus Labs, an API and contract manufacturing company, is the multibagger pharma stock behind a return of approximately 129% in one year. The share climbed from around Rs 847 to near Rs 1,940 as CDMO revenue surged, Q1 FY27 profit more than doubled and margins crossed 31%. Valuations are now rich at a PE near 96, and the share already trades close to most brokerage targets.<\/p>\n<\/div>\n

This multibagger pharma stock has more than doubled investor money in the past twelve months, turning Rs 1 lakh into roughly Rs 2.29 lakh. One Hyderabad-based drug maker delivered a 1-year return of 129.01% as of 10 September 2026, ranking seventh in a screen of 101 large-cap and mid-cap NSE shares.<\/p>\n

The company is Laurus Labs Ltd<\/a> (NSE: LAURUSLABS)<\/strong>, a maker of active pharmaceutical ingredients, finished generic medicines and contract manufacturing services for global drug innovators. The Laurus Labs share price moved from approximately Rs 847 a year ago to around Rs 1,940 on 10 September 2026, and the company is now valued at approximately Rs 1,04,456 crore, ahead of several older pharma names.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n